TDP-43 in neurodegenerative disorders
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The number of neurodegenerative diseases associated with pathological aggregates of transactivation response element (TAR)-DNA-binding protein 43 (TDP-43) has increased, leading to the new designation 'TDP-43 proteinopathy.' Biochemically, TDP-43 proteinopathies are characterized by decreased solubility, hyperphosphorylation, and cleavage of TDP-43 into 25- and 35-kDa fragments, and by altered cellular localization. OBJECTIVE: This review summarizes research characterizing the distribution of TDP-43 pathology in human postmortem brain tissue and discusses possible therapeutic strategies based on genetic and in vitro studies. METHODS: We reviewed recent studies of TDP-43 proteinopathy. RESULTS/CONCLUSION: Given that several different mutations can lead to TDP-43 proteinopathies, including mutations in progranulin and valosin-containing protein, research is needed to decipher and potentially exploit the link between these mutations and TDP-43 pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Self-citationCruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512 · cited 11×
“Because PGRN mutations associated with FTLD-U are hypothesized to lead to a loss of functional PGRN [37-39], the demonstration that decreased PGRN expression in vitro increases TDP-43 cleavage via caspase activation provides the first mechanistic link between PGRN haploinsufficiency and TDP-43 pathology; however a sub…”
BackgroundInfluentialWatts, G. D. J., Wymer, J., Kovach, M. J., Mehta, S. G., Mumm, S., Darvish, D., Pestronk, A., Whyte, M. P., & Kimonis, V. E. (2004) · Nature Genetics · doi:10.1038/ng1332 · Cited by 1,391 · cited 6×
“In addition, given the link between TDP-43 proteinopathies and mutations in PGRN and VCP, evaluating TDP-43 expression, function, and localization in various mutant and knockout models of PGRN and VCP might explain the link between these proteins.”
BackgroundInfluentialTau is a candidate gene for chromosome 17 frontotemporal dementia
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., & Schellenberg, G. D. (1998) · Annals of Neurology · doi:10.1002/ana.410430617 · Cited by 1,374 · cited 4×
“Although mutations in tau are known to FTDP-17 [35,36], the most common familial tauopathy, an additional linkage to Expert Opin Biol Ther.”
BackgroundInfluentialHDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.
Pandey, U. B., Nie, Z., Batlevi, Y., McCray, B. A., Ritson, G. P., Nedelsky, N. B., Schwartz, S. L., DiProspero, N. A., Knight, M. A., Schuldiner, O., et al. (2007) · Nature · doi:10.1038/nature05853 · Cited by 1,234 · cited 1×
“Stimulation of autophagy by overexpressing histone deacetylase 6 (HDAC6) in Drosophila suppressed degenerative phenotypes caused by UPS impairment resulting from the overexpression of either Aβ fragments (unpublished observations reported in [76]) or polyQ-expanded proteins [76].”
BackgroundSarkar, S., Davies, J. E., Huang, Z., Tunnacliffe, A., & Rubinsztein, D. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609532200 · Cited by 1,142
Cairns, N. J., Bigio, E. H., Mackenzie, I. R. A., Neumann, M., Lee, V. M.-Y., Hatanpaa, K. J., White, C. L., Schneider, J. A., Grinberg, L. T., Halliday, G., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0237-2 · Cited by 1,110 · cited 3×
“Given that most researchers utilized the Sampathu classification system, the remainder of this review will refer to the subtypes as defined by that group [1,32].”
BackgroundMethodSelf-citationMolecular biology of amyotrophic lateral sclerosis: insights from genetics
Pasinelli, P., & Brown, R. H. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1971 · Cited by 1,107 · cited 2×
“Although most ALS cases are sporadic, approximately 10% of patients have a positive family history [49].”
BackgroundMackenzie, I. R. A., Bigio, E. H., Ince, P. G., Geser, F., Neumann, M., Cairns, N. J., Kwong, L. K., Forman, M. S., Ravits, J., Stewart, H., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21147 · Cited by 992 · cited 4×
“Although TDP-43 appears to be the major constituent of inclusions in motor and non-motor neurons in ALS and FTLD-MND [2,23-26], some inclusions in ALS, particularly familial forms of ALS, show no TDP-43 immunoreactivity [27,28].”
BackgroundInfluentialTDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916 · cited 5×
“Although investigators have not detected TDP-43 pathology in classic tauopathies, including corticobasal degeneration and progressive supranuclear palsy, as well as familial FTLD cases with tau mutations [65], tau pathology associated with Alzheimer's disease (AD) is sometimes associated with TDP-43 pathology [69].”
BackgroundResultInfluentialSelf-citationMutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia
Skibinski, G., Parkinson, N. J., Brown, J. M., Chakrabarti, L., Lloyd, S. L., Hummerich, H., Nielsen, J. E., Hodges, J. R., Spillantini, M. G., Thusgaard, T., et al. (2005) · Nature Genetics · doi:10.1038/ng1609 · Cited by 822 · cited 3×
“Additional genetic mutations that have been linked to FTLD-U include valosin-containing protein (VCP) [40-42], charged multivesicular body protein 2B (CHMP2B) [43], as well as a newly identified genetic locus on chromosome 9p, which might result from mutations in intraflagellar transport protein 74 [44].”
BackgroundFilimonenko, M., Stuffers, S., Raiborg, C., Yamamoto, A., Malerød, L., Fisher, E. M. C., Isaacs, A., Brech, A., Stenmark, H., & Simonsen, A. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200702115 · Cited by 626 · cited 1×
“Recent data have demonstrated that TDP-43 pathology increased when either proteasomal or autophagic pathways were inhibited in vitro [34,75].”
BackgroundFrontotemporal dementia: Clinicopathological correlations
Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., Chatterjee, A., Hurtig, H. I., Karlawish, J. H., Rosen, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20873 · Cited by 478
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases
Nakashima-Yasuda, H., Uryu, K., Robinson, J., Xie, S. X., Hurtig, H., Duda, J. E., Arnold, S. E., Siderowf, A., Grossman, M., Leverenz, J. B., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0261-2 · Cited by 468 · cited 3×
“In a subsequent study that evaluated the incidence of TDP-43 pathology in Lewy body disorders, TDP-43-positive inclusions were observed in 30% of AD cases with concomitant dementia with Lewy bodies (DLB), 7% of Parkinson’s disease (PD) cases, and 19% of PD cases with dementia [70] .”
BackgroundInfluentialLeverenz, J. B., Yu, C. E., Montine, T. J., Steinbart, E., Bekris, L. M., Zabetian, C., Kwong, L. K., Lee, V. M.-Y., Schellenberg, G. D., & Bird, T. D. (2007) · Brain · doi:10.1093/brain/awm069 · Cited by 129
Classification and Description of Frontotemporal Dementias
NEARY, D., SNOWDEN, J. S., & MANN, D. M. A. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06904.x · Cited by 99 · cited 10×
“Cases of FTLD-U associated with motor neuron disease (MND), sometimes resembling ALS, are referred to as FTLDMND.”
BackgroundInfluential
Cited by
TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration
Lagier-Tourenne, C., Polymenidou, M., & Cleveland, D. W. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq137 · Cited by 1,021
Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice
Yin, F., Banerjee, R., Thomas, B., Zhou, P., Qian, L., Jia, T., Ma, X., Ma, Y., Iadecola, C., Beal, M. F., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091568 · Cited by 480
“Recent studies have linked pathological redistribution of TDP-43 from nuclei to cytoplasm to its phosphorylation and degradation (Cook et al., 2008; Hasegawa et al., 2008).”
BackgroundAhmed, Z., Sheng, H., Xu, Y.-F., Lin, W.-L., Innes, A. E., Gass, J., Yu, X., Hou, H., Chiba, S., Yamanouchi, K., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090915 · Cited by 294
Self-citationSchwab, C., Arai, T., Hasegawa, M., Yu, S., & McGeer, P. L. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818e8951 · Cited by 271
Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation
Tziortzouda, P., Van Den Bosch, L., & Hirth, F. (2021) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00431-1 · Cited by 267
Metadata
- Authors
- Cook, C., Zhang, Y.-J., Xu, Y.-F., Dickson, D. W., & Petrucelli, L.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2008-06-12
- Volume
- 8
- Issue
- 7
- Pages
- 969-978
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2006096915
- Cited by
- 48
- References
- 17
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.